Division of Pediatrics, Zhejiang General Hospital of Armed Police Forces, 16 South Lake Road, Jiaxing City 314000, China.
J Transl Med. 2013 Jan 26;11:21. doi: 10.1186/1479-5876-11-21.
Stem cell therapy is a promising treatment for cerebral palsy, which refers to a category of brain diseases that are associated with chronic motor disability in children. Autologous MSCs may be a better cell source and have been studied for the treatment of cerebral palsy because of their functions in tissue repair and the regulation of immunological processes.
To assess neural stem cell-like (NSC-like) cells derived from autologous marrow mesenchymal stem cells as a novel treatment for patients with moderate-to-severe cerebral palsy, a total of 60 cerebral palsy patients were enrolled in this open-label, non-randomised, observer-blinded controlled clinical study with a 6-months follow-up. For the transplantation group, a total of 30 cerebral palsy patients received an autologous NSC-like cells transplantation (1-2 × 107 cells into the subarachnoid cavity) and rehabilitation treatments whereas 30 patients in the control group only received rehabilitation treatment.
We recorded the gross motor function measurement scores, language quotients, and adverse events up to 6 months post-treatment. The gross motor function measurement scores in the transplantation group were significantly higher at month 3 (the score increase was 42.6, 95% CI: 9.8-75.3, P=.011) and month 6 (the score increase was 58.6, 95% CI: 25.8-91.4, P=.001) post-treatment compared with the baseline scores. The increase in the Gross Motor Function Measurement scores in the control group was not significant. The increases in the language quotients at months 1, 3, and 6 post-treatment were not statistically significant when compared with the baseline quotients in both groups. All the 60 patients survived, and none of the patients experienced serious adverse events or complications.
Our results indicated that NSC-like cells are safe and effective for the treatment of motor deficits related to cerebral palsy. Further randomised clinical trials are necessary to establish the efficacy of this procedure.
干细胞疗法是脑瘫的一种有前途的治疗方法,脑瘫是指一类与儿童慢性运动残疾相关的脑部疾病。自体间充质干细胞可能是更好的细胞来源,并因其在组织修复和免疫过程调节中的功能而被研究用于治疗脑瘫。
为了评估源自自体骨髓间充质干细胞的神经干细胞样(NSC-样)细胞作为一种治疗中重度脑瘫患者的新方法,共纳入 60 例脑瘫患者进行了这项为期 6 个月随访的开放性、非随机、观察者设盲对照临床试验。对于移植组,共 30 例脑瘫患者接受了自体 NSC-样细胞移植(1-2×107 个细胞到蛛网膜下腔)和康复治疗,而对照组 30 例患者仅接受康复治疗。
我们记录了治疗后 6 个月内的粗大运动功能测量评分、语言商数和不良事件。移植组的粗大运动功能测量评分在第 3 个月(评分增加 42.6,95%CI:9.8-75.3,P=.011)和第 6 个月(评分增加 58.6,95%CI:25.8-91.4,P=.001)时明显高于基线评分。对照组的粗大运动功能测量评分增加不显著。两组患者的语言商数在治疗后 1、3 和 6 个月与基线商数相比均无统计学意义。60 例患者全部存活,无患者发生严重不良事件或并发症。
我们的结果表明,NSC-样细胞治疗脑瘫相关运动障碍是安全有效的。需要进一步的随机临床试验来确定该治疗程序的疗效。